RT Journal Article
SR Electronic
T1 Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine: A Study of MR Imaging and Inductively Coupled Plasma Atomic Emission Spectroscopy in Rat Brain Tumors
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 15
OP 18
VO 23
IS 1
A1 Zhang, Tian
A1 Matsumura, Akira
A1 Yamamoto, Tetsuya
A1 Yoshida, Fumiyo
A1 Nose, Tadao
A1 Shimojo, Nobuhiro
YR 2002
UL http://www.ajnr.org/content/23/1/15.abstract
AB BACKGROUND AND PURPOSE: After the advent of extracellular contrast media, hepatobiliary-specific gadolinium chelates were developed to improve the diagnostic value of MR imaging of the liver. Gadobenate dimeglumine (Gd-BOPTA) is a new paramagnetic contrast agent with partial biliary excretion that produces prolonged enhancement of liver parenchyma on T1-weighted images. However, whether Gd-BOPTA is useful as a contrast agent in central nervous system disease, particularly in brain tumors, is unclear.METHODS: The behavior of Gd-BOPTA as a brain tumor–selective contrast agent was compared with that of gadopentetate dimeglumine (Gd-DTPA), an MR contrast agent used in central nervous system disease, in a common dose of 0.1 mmol/kg. An MR imaging study of these two contrast agents was performed, and tissue concentrations were measured with inductively coupled plasma atomic emission spectroscopy (ICP-AES).RESULTS: Gd-BOPTA showed better MR imaging enhancement in brain tumors than did Gd-DTPA at every time course until 2 hours after administration and no enhancement in peritumoral tissue and normal brain. Corresponding results with ICP-AES showed significantly greater uptake of Gd-BOPTA in tumor samples than that in peritumoral tissue and normal brain 5 minutes after administration. Gadolinium was retained for a longer time in brain tumors when Gd-BOPTA rather than Gd-DTPA was administered.CONCLUSION: Gd-BOPTA is a useful contrast agent for MR imaging in brain tumors and possibly an effective absorption agent for neutron capture therapy.